HJLI - Hancock Jaffe Laboratories ( Nasdaq )

tfly

Nuovo Utente
Registrato
29/8/02
Messaggi
7.524
Punti reazioni
166
...vediamo se domani riesco a salire in sella prima che realizzi ...,:confused:
 
Buongiorno, ci sono notizie sul perchè di questa impennata? Qualche nuova scoperta?
 
Non pare esserci grande interesse per ora :confused:
 
E intradabile
 
... anche qua se non arriva una news da mozzare il fiato è da calma piatta...:rolleyes:
 
... anche qua se non arriva una news da mozzare il fiato è da calma piatta...:rolleyes:

io penso che arrivera lamandan giu con niente e poi si piazzano con pezzi piu grossi sopra
e impossibile , almeno per me riuscire a prenderle se non i lettera e a vista non piazzano mai pezzature decenti e si corre il rischio di scorstarla del 10 per cento:rolleyes:
 
...inizia a cedere? :rolleyes:
 
chart.ashx


Hancock Jaffe Laboratories, Inc., a development stage company, develops and sells biological based tissue solutions for patients with cardiovascular disease, and peripheral arterial and venous disease in the United States and Europe. The company develops and manufactures bioprosthetic implantable devices for cardiovascular diseases, including the VenoValve, a porcine based device to be surgically implanted in the deep venous system of the leg to treat chronic venous insufficiency; the CoreoGraft, a bovine based off the shelf conduit to be used to revascularize the heart during coronary artery bypass graft surgeries; and the Bioprosthetic Heart Valve, a porcine based heart valve designed to function like a native heart valve used for pediatric heart valve recipients. It also provides research, development, and contract manufacturing services. Hancock Jaffe Laboratories, Inc. was founded in 1987 and is based in Irvine, California.
 
si attendono news
che dovrebbero essere molto buone
target 2 $
 
Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa to Present Updated VenoValve Data Next Week at the 32nd Annual Meeting of the American Venous Forum
Wednesday, February 26, 2020 8:30 AM
Updated VenoValve data will include 8 Patients at 180 days - including 1 Patient at 365 Days Post VenoValve Surgery

IRVINE, CA / ACCESSWIRE / February 26, 2020 / Hancock Jaffe Laboratories, Inc. (Nasdaq:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that on Wednesday, March 4, 2020, Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI's first-in-man VenoValve study in Colombia, will present updated VenoValve data at the Thirty Second Annual Meeting of the American Venous Forum. The meeting is taking place March 3 to March 6 at the Omni Amelia Island Plantation Hotel at Amelia Island, Florida.

Contemporaneously with Dr. Ulloa's presentation at the American Venous Forum meeting, HJLI will release select VenoValve data from the presentation, which will include updated reports from 8 patients that are 180 days post VenoValve surgery (including 1 Patient that is now 365 days post VenoValve surgery).

The VenoValve is currently undergoing a first-in-man study in Colombia and was developed to treat chronic venous insufficiency ("CVI") due to valvular incompetence of the deep vein system. CVI is a condition that occurs when the valves in the veins of the leg are injured or destroyed, causing blood to flow backwards. The backwards flow of blood is known as reflux, and leads to the pooling of blood in the lower leg and increased venous pressure (venous hypertension) in the veins of the leg.

Endpoints for the VenoValve first-in-man study include reflux, measured by doppler, a VCSS score used by the clinician to measure disease severity, a VAS score used by the patient to measure pain, and VEINES qol/sym used to measure quality of life.

HJLI will submit the data from its first-in-man Colombia study as part of its Investigational Device Exemption ("IDE") application to be submitted to the U.S. Food and Drug Administration ("FDA") in order to begin the U.S. pivotal trial for the VenoValve. HJLI expects to file the IDE application in Q3 of 2020.

Approximately 2.4 million people in the U.S. suffer from CVI due to reflux in the deep venous system. Patients with venous ulcers from CVI in the U.S. spend an average of approximately $30,000 per year on wound care. Estimates indicate that direct medical costs from CVI in the U.S. exceed $30 Billion per year. There are currently no FDA approved devices or effective treatments for deep venous CVI.

The American Venous Forum (AVF) is dedicated to improving the care of patients with venous and lymphatic disease. Founded in 1987, AVF fosters cutting edge research and clinical innovation and educates health care professionals, patients and policy makers about venous and lymphatic diseases.

AVF's leadership and membership are recognized internationally as thought leaders, expert investigators and clinicians in venous and lymphatic disease.


fonte : Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa to Present Updated VenoValve Data Next Week at the 32nd Annual Meeting of the American Venous Forum




... si inizia a far sul serio :D
 
speriamo, fino adesso non ho visto niente, anzi e_piu bassa da quando ho comperato
 
...ci vuole tanta fiducia di questi tempi...:)
 
per ora tiene meglio di altre... nonostante il coronavirus
 
Indietro